A recent report indicated that an ongoing phase 1 study aims to identify the recommended expansion dose and assess the preliminary efficacy of MLN0128 and CB-839 in treating lung squamous cell carcinoma and KRAS-mutant lung adenocarcinoma[35]. Here, KRAS is linked to squamous cell lung carcinoma.